Literature DB >> 16225480

HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3?

A Grassi1, G Ballardini, M Susca, F Bianchini, S Bonoli, F B Bianchi, M Lenzi.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is associated with the appearance of liver steatosis. AIM: To search for a correlation between the number of HCV infected hepatocytes and the presence, amount and distribution of steatosis.
METHODS: A total of 124 frozen liver biopsies from HCV patients (genotype 3 = 21) were studied. HCV-antigens were detected on frozen liver sections using a four steps immunoperoxidase technique. Steatosis was graded by haematoxilin-eosin counterstaining on a serial section.
RESULTS: Steatosis was detected in 82 of 124 (66.1%) patients without differences between different genotypes. Uric acid, body mass index, gammaGT levels significantly correlated with steatosis in non-3 (P < 0.01, P < 0.05, P < 0.01, respectively) but not in genotype 3 patients. HCV-antigens were detected in 95 of 124 (76.6%) cases. A positive correlation between steatosis and the number of infected hepatocytes was observed only in genotype 3 patients (P = 0.06). In most cases the number of cells with steatosis greatly outnumbered that of HCV infected cells.
CONCLUSION: We confirm a possible role of the virus in the genesis of steatosis in HCV genotype 3 infected patients; however, as steatosis do not appear to be directly related to the presence of HCV-antigens within single hepatocytes, an indirect, possibly cytokine mediated, mechanism might be operative.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225480     DOI: 10.1111/j.1365-2036.2005.02603.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.

Authors:  Jose-Eymard Medeiros-Filho; Isabel-Maria-Vicente-Guedes de Carvalho Mello; Joao-Renato-Rebello Pinho; Avidan-U Neumann; Fernanda de Mello Malta; Luiz-Caetano da Silva; Flair-Jose Carrilho
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

Review 2.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

3.  Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

4.  Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis.

Authors:  Marion Depla; Louis d'Alteroche; Amélie Le Gouge; Alain Moreau; Christophe Hourioux; Jean-Christophe Meunier; Julien Gaillard; Anne de Muret; Yannick Bacq; Farhad Kazemi; Aurélie Avargues; Emmanuelle Roch; Eric Piver; Catherine Gaudy-Graffin; Bruno Giraudeau; Philippe Roingeard
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.